Sweden
LIPUM AB, a trailblazer in the Biotechnology and Health Care sectors, has developed SOL-116, a groundbreaking biological drug targeting chronic inflammatory diseases. Since its inception in 2010, the company has been committed to improving the quality of life for millions affected by these debilitating conditions, significantly reducing the burden on individuals and society.
Located in Sweden, LIPUM's innovative approach addresses the pain, disability, and comorbidities often faced by those with chronic inflammation, ultimately aiming to ease healthcare and societal costs. The recent investment influx of kr79.70M in a Post-IPO Equity round on 23 April 2024 underscores investor confidence in LIPUM's potential to revolutionize treatment in this landscape.
The absence of disclosed investor names in their latest funding round leaves room for strategic partnerships in the near future, presenting prospective investors an opportunity to influence the company's next growth phase.
